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MacrophageSingle nucleotide polymorphisms near the Ink4/Arf locus have been associated with type-2 diabetes mellitus.
Previous studies indicate a protective role of the locus in the carbohydrate metabolism derangement associated
with ageing inwild-typemice. The present study demonstrates that the increased Ink4/Arf locus expression in 1-
year-old mice, partially-deﬁcient for the insulin receptor substrate (IRS)2 (Irs2+/−SuperInk4/Arfmice) amelio-
rates hepatic steatosis, inﬂammation and insulin resistance. Irs2+/−SuperInk4/Arfmice displayed improved glu-
cose tolerance and insulin sensitivity compared with Irs2+/−mice which were glucose intolerant and insulin
resistant comparedwith age-matched wild-typemice. These changes in Irs2+/−micewere accompanied by en-
hanced hepatic steatosis, proinﬂammatory macrophage phenotype, increased Ly6Chi-monocyte percentage, T-
lymphocyte activation andMCP1 and TNF-α cytokine levels. In Irs2+/−SuperInk4/Arfmice, steatosis and inﬂam-
matory parameters weremarkedly reduced and similar to those of wild-type counterparts. In vivo insulin signal-
ling also revealed reduced activation of the IRS/AKT-dependent signalling in Irs2+/− mice. This was restored
upon increased locus expression in Irs2+/−SuperInk4/Arfmice which display similar activation levels as those
for wild-type mice. In vivo treatment of Irs2+/−SuperInk4/Arf mice with TNF-α diminished insulin canonical
IRS/AKT-signalling and enhanced the stress SAPK/JNK–phosphoSer307IRS1-pathway suggesting that cytokine
levels might potentially affect glucose homeostasis through changes in these insulin-signalling pathways. Alto-
gether, these results indicate that enhanced Ink4/Arf locus expression restores glucose homeostasis and that
this is associated with diminished hepatic steatosis and inﬂammation in mice with insulin resistance. Therefore,
pharmacological interventions targeted tomodulate the Ink4/Arf locus expression could be a tentative therapeu-
tic approach to alleviate the inﬂammation associated with insulin resistance.
Published by Elsevier B.V.1. Introduction
Type 2 diabetes mellitus (T2DM) constitutes a major problem to
global health, and its incidence has increased at an alarming rate as a re-
sult of the acquisition of unhealthy life habits (sedentariness, excessiveaktmurine thymomaviral onco-
,stress-activatedproteinkinase/
; BW, bodyweight; CDK, cyclin-
esistance; ITT, insulin tolerance
CLIVA, Avd. Menéndez Pelayo,
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).caloric intake) and population ageing [1]. Patients with T2DM are at a
higher risk of cardiovascular disease and have a shorter lifespan com-
pared to the general population [2].
Alterations exhibited by T2DM patients include glucose intolerance,
decreased insulin sensitivity and β-cell dysfunction [3]. Insulin receptor
substrate 2 (IRS2)-mediated signalling integrates insulin metabolic
effects in target tissues and, in pancreatic islets, is involved in glucose
sensing, β-cell growth and insulin secretion [4,5]. Thus, total ablation
of IRS2 in the mouse produces hyperglycaemia, glucose intolerance,
insulin resistance (IR), reduced β-cell mass and premature death [4].
A single copy of IRS2, nevertheless, does not affect mouse survival and
is sufﬁcient to maintain appropriate β-cell compensatory hyperplasia
as a response to peripheral IR in young animals [5]. At 6-months
of age, however, Irs2+/− mice have moderate IR [5]. But when fed
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Moreover, partial inactivation of Irs2 in hypercholesterolaemic apolipo-
protein E-deﬁcient mice produces glucose intolerance, moderate
hyperinsulinaemia and accelerates atherosclerosis [7]. In addition,
when combined with insulin receptor haploinsufﬁciency, Irs2-partial
inactivation increases the frequency of diabetes in mice [8]. In humans,
IRS2 reduced expression has been found in β-cells from T2DM patients
[9] and in circulating leukocytes from metabolic-syndrome patients
with IR [7]. Functional alterations in IRS2 provoked by allelic variants
also contribute to IR in women with polycystic ovary syndrome [10],
inﬂuence glucose homeostasis in premenopausal women [11] and
predispose to T2DM in obese subjects [12]. These studies indicate that
reduced IRS2 expression, when combined with other metabolic disor-
ders (i.e., high fat-feeding, hypercholesterolemia, metabolic syndrome),
predisposes to IR, therefore, therapeutic strategies to ameliorate the ef-
fects of IRS2-impaired signalling in target tissues might be effective at
preventing these syndromes.
Human genome-wide association studies using large cohorts have
linked common genetic variants in a region of chromosome 9p21 in
close vicinity to the Ink4a/Arf/Ink4b locus (hereby abbreviated as Ink4/
Arf) with T2DM [13–20]. This complex locus encompasses the genes
CDKN2A, which encodes the tumour suppressors p16Ink4a and ARF
(p14Arf in humans, p19Arf in mice), and CDKN2B, which encodes the tu-
mour suppressor p15Ink4b. A non-coding antisense RNA named ANRIL
(antisense noncoding RNA in the INK4 locus, CDKN2BAS) has also
been found within the human Ink4a/Arf locus [21]. Whilst p16Ink4a and
p15Ink4b are potent cell cycle inhibitors through binding to CDK4,6/cy-
clin D kinases [22], ARF mainly exerts a proapoptotic activity via the in-
hibition of MDM2, an ubiquitin-ligase that destabilises the tumour
suppressor p53 [23]. The mechanisms coupling the Ink4/Arf locus vari-
ants, its gene activity and glucose metabolism are very poorly known.
In humans, speciﬁc isoforms of CDKN2BAS have been shown to regulate
key genes of glucose and fatty acidmetabolism [24]. Variants within the
CDKN2B gene have been linked to changes in HOMA-IR [25] whilst
others have been associatedwith reduced pancreatic islet insulin secre-
tion [26,27]. In mice, reduced regenerative capacity of β-cells has been
reported in streptozotocin-treated diabeticmicewith increased expres-
sion of the proteins encoded by the Ink4/Arf locus [28]. That notwith-
standing, the increased expression of the Ink4/Arf locus alleviates
glucose intolerance and IR developed by aged WT mice [29]. These
seemingly discrepant results are probably due to the complexity of the
Ink4/Arf locus which results in divergent contributions of the genes in
response to different stimuli. Thus, the locus has detrimental effects
on acute damage of the pancreas by streptozotocin treatment [28,30]
and beneﬁcial effects in normal ageing [29].
Whether the protective mechanisms of the Ink4/Arf locus might be
beneﬁcial in mouse models that develop IR remains to be established.
The present study has investigated the effect of increased Ink4/Arf locus
expression on glucose homeostasis in mice with partial deﬁciency in
IRS2, which, as mentioned above, is frequently associated with a variety
ofmetabolic disorders andmight predispose to IR in humans and inmice
[5–11]. To this end, this study has used SuperInk4/Arfmice,which bear an
extra dosage of the Ink4/Arf locus and display an age-dependent expres-
sion of the transgene [31,32] to generate Irs2+/−SuperInk4/Arfmice.
Glucose metabolism, systemic inﬂammation, macrophage properties
and liver characteristics were investigated in these doubly-mutant
mice and compared to age-matched Irs2+/− andWTmice, with a nor-
mal dosage of the locus.
2. Materials and methods
2.1. Mice
Animal carewas in accordancewith institutional guidelines and reg-
ulations. Transgenic SuperInk4/Arfmice used in this study carried one
extra copy of the entire Ink4/Arf locus [32] and were obtained after 20backcrosses into C57BL6/J background. Crosses between Irs2+/−
(also in a C57BL6/J background) and SuperInk4/Arfmice generated the
three experimental groups, WT, Irs2+/− and Irs2+/−SuperInk4/Arf
mice and were identiﬁed by genotyping to detect the extra Ink4/Arf
copy [32] and Irs2 deﬁciency [7]. Male mice of one year of age were
used for the study. All the mice were siblings, were on C57BL6/J back-
ground and were bred and kept on a low-fat standard diet (2.8% fat;
Panlab, Barcelona, Spain) in the same animal facility.
2.2. Metabolic measurements and body fat mass distribution
For the glucose tolerance test (GTT), 15 h-fasted mice received an
intraperitoneal injection of glucose (2 g/kg of body weight (BW),
Sigma, St. Louis, MI, USA) and glucose and insulin levels were analysed
from tail blood at different time points using a glucometer (Bayer,
Leverkusen, Germany) and an ultrasensitive anti-mouse insulin ELISA
(Mercodia, Uppsala, Sweden) respectively. For the insulin tolerance
test (ITT), 4 h-fasted mice received an intraperitoneal injection of
insulin (0.5 U/kg of BW, Actrapid, NovoNordisk, Bagsvaerd, Denmark)
and glucose levels were measured at different time points. HOMA-IR
index was determined by using the following formula: fasting plasma
glucose (mmol/l) × fasting plasma insulin (μU/L) / 22.5. Liver triglycer-
ide content was determined by tissue digestion and saponiﬁcation in
ethanolic potassium hydroxide [33], followed by an enzymatic mea-
surement of glycerol content (Free Glycerol Reagent, Sigma-Aldrich).
For body fat mass distribution, inguinal, epididymal and mesenteric fat
was dissected frommouse bodies, weighed and expressed as a percent-
age of body weight.
2.3. Liver and pancreas characterisation
For immunohistopathological analysis, livers and pancreaswere sec-
tioned from mice, washed with PBS, ﬁxed with 4% paraformaldehyde/
PBS for 4 h, washed with PBS and parafﬁn-embedded as previously de-
scribed [29]. A researcher blinded to genotype analysed β-cell mass,
measured as the area of pancreatic islets relative to total pancreatic
area (%), and as pancreatic islet number relative to pancreatic area. Pan-
creatic islets were identiﬁed by insulin immunostaining (described
below) in 10–12 slides per mouse, separated 125 μm. Lipid droplet
(LD) content in liver was performed in haematoxylin–eosin-stained
sections.
For the immunohistochemistry the protocol consisted of peroxidase
inactivation (H2O2 0.3% in distilled water), antigen retrieval with a sodi-
um citrate buffer (10 mM, pH 6.5), incubation with primary antibodies
(anti-insulin 1/200 dilution, sc-9168, Santa Cruz Biotechnology, Santa
Cruz, CA, USA; prediluted rabbit anti-Ki67 monoclonal antibody Clone
SP6;MAD-000310QD, Vitro, Granada, Spain; rat anti-F4/80 1/50 dilution,
MCA497G, AbD Serotec, ThermoFisher, Kidlington, UK) followed by bio-
tinylated goat anti-rat or anti-rabbit secondary antibody (1/500 dilution,
sc-2491, sc-2041, Santa Cruz Biotechnology), streptavidin-HRP (TS-060-
HR, ThermoScientiﬁc, Cheshire, UK) and DAB substrate (SK4100, Vector
Laboratories, Burlingame, CA, USA). Slides were counterstained with
haematoxylin and mounted with EUKITT (A10500, Deltalab, Barcelona,
Spain). Images were captured with an OPTIKAM-PRO5 digital camera
mounted on a stereomicroscope (OPTIKA, Barcelona, Spain) and analysed
by computer-assisted morphometry (SigmaScan, Pro5).
2.4. Islet isolation
Islet isolation was performed as previously described [29]. Mice
were infused with Krebs buffer (127 mM NaCl, 5 mM KCl, 3 mM CaCl2,
1.5 mM MgCl2, 24 mM NaHCO3, 6 mM Hepes, 2 mg/mL glucose, 0.1%
albumin, equilibratedwith 5% CO2 in O2) and their pancreaseswere dis-
sected and digestedwith collagenase-NB8 (1mg/mL, Serva, Heidelberg,
Germany) at 37 °C in a shaking water bath for 20 min. Islets were
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later analyses.
2.5. Western blot analysis
Protein extracts were obtained from the tissues using a homogeniser
in the presence of the ice-cold lysis TNG buffer (Tris–HCl 50mM, pH 7.5,
NaCl 200 mM, Tween-20 1%, NP-40 0.2%) supplemented with Complete
Mini cocktail, PhosSTOP (Roche, Mannheim, Germany), ß-glycerol phos-
phate 50 mM (Sigma, St. Louis, MO, USA), 2 mM phenylmethylsulfonyl
Fluoride (PMSF, Roche, Mannheim, Germany) and 200 μM Na3VO4
(Sigma). For total protein analysis, protein extracts (35–75 μg) were
analysed by 12% or 15% polyacrylamide gel electrophoresis andWestern
blot, as reported [7]. Co-immunoprecipitation experiments were per-
formed as previously described [29]. Protein extracts (500 μg)were incu-
bated 1 h at 4 °C with 2 μg of rabbit polyclonal anti-IRS1 (sc-559, Santa
Cruz Biotechnology), followed by an incubation (overnight, 4 °C) with
30 μL of 50% Protein A/G PLUS-Agarose (sc-2003, Santa Cruz Biotechnol-
ogy) and then, beadswerewashed twice (16,000 g, 5 s) with TNG buffer.
Immunoglobulin–protein complexes were eluted from beads by boiling
in Laemmli's buffer (25 μL) and were subjected to 8% polyacrylamide
gel electrophoresis and Western blot analysis.
The following primary antibodies were used for the Western blot
analysis: rabbit polyclonal IgG anti-phospho-Akt (Ser473) (1/250, 9271
Cell Signaling Technology, Boston, MA, USA), goat polyclonal IgG anti-
Akt1/2 (1/1000, sc-1619 Santa Cruz Biotechnology), mouse anti-
phospho-Tyr (1/500, clone 4G10, 05-321, Upstate, Millipore, Madrid,
Spain), rabbit anti-IRS1 (1/1500, 2382 Cell Signaling), rabbit polyclonal
anti-phosphoSer307IRS1 (1/1500, 2381 Cell Signaling Technology),
rabbit anti-p16Ink4a and anti-p19Arf (1/200, Santa Cruz Biotechnology,
sc-1207 and sc-32748), rabbit anti-p15Ink4b (1/500, 4822 Cell Signaling
Technology), rabbit polyclonal anti-Phospho-SAPK/JNK (1/100, Thr183/
Tyr185, 9251 Cell Signaling Technology), rabbit polyclonal SAPK/JNK
(1/200, 56G8, 9258 Cell Signaling Technology) and mouse anti-β-actin
(1/500, A5441, Sigma). The HRP-conjugated secondary antibodies (all
from Santa Cruz Biotechnology, 1/3000) used were the following: anti-
mouse IgG-HRP (sc-2031), goat anti-rabbit IgG-HRP (sc-2004) and don-
key anti-goat IgG-HRP (sc-2056). The immunocomplexes were detected
with an ECL Plus detection kit (ThermoFisher Scientiﬁc, Barcelona,
Spain).
2.6. Enzyme-linked immunosorbent assay (ELISA)
MCP1 and TNF-α circulating levelswere determined in isolated plas-
ma from heparinised blood (10 U heparin/mL) of WT, Irs2+/− and
Irs2+/−SuperInk4/Arfmice using the Quantikine ELISA kits (R&D Sys-
tems, Minneapolis, MN, USA).
2.7. Leukocyte analysis by ﬂow cytometry
For the study of circulating monocytes, 10 μL of heparinized whole
blood was incubated for 30 min at RT with CD45-FITC, Ly6C-PerCP
(553080 and 560525 from BD Pharmingen, Madrid, Spain) and
CD115-APC (135509 Biolegend, San Diego, CA, USA). After incubation
with lysing solution (BD FACS Lysing Solution) samples were analysed
by ﬂow cytometry (FACSVerse Flow cytometer, BD Biosciences, San
Jose, CA, USA) to determine Ly6Clow and Ly6Chi in CD45+CD115+pop-
ulations as previously described [34]. For the study of circulating
lymphocytes, 10 μL of heparinised whole blood was incubated for
30 min at room temperature with 5 μL Brilliant Stain Buffer (563794,
BD) and with the following antibodies: Brilliant violet (BV) conjugated
rat anti-mouse CD4 (562891, BD), Brilliant violet (BV) conjugated rat
anti-mouse CD8a (563068, BD), phycoerythrin (PE) conjugated with
hamster anti-mouse CD69 (553237, BD) and allophycocyanin (APC)
hamster anti-mouse CD3e (553066, BD). Incubation with lysingsolution (BD FACS Lysing Solution) was done before analysis of markers
by ﬂow cytometry (FACSVerse Flow cytometer, BD Biosciences).2.8. Gene expression analysis by quantitative real-time PCR (qPCR)
RNA (0.5–1 μg) from mouse liver and macrophages, obtained using
TRIzol Reagent (Invitrogen Carlsbad, CA, USA), was retrotranscribed
with the Maxima First-Strand cDNA Synthesis kit and ampliﬁed with
Luminars Colour-HiGreen/High ROX qPCR MasterMIX (Fermentas,
Madrid, Spain) on a thermal Cycler 7900 Fast System as previously de-
scribed [35]. Resultswere analysedwith theprovided software (Applied
Biosystems, Madrid, Spain). The mRNA levels were normalised to en-
dogenous gene Cyclophilin expression and relativised to WT mRNA
levels. The primers used were designed with the primer express pro-
grammeandwere the following (Forward: Fw; Reverse: Rv): cyclophilin
Fw: 5′-TGGAGAGCACCAAGACAGACA-3′ and Rv: 5′-TGCCGGAGTCGACA
ATGAT-3′; p15Ink4b Fw 5′-AGATCCCAACGCCCTGAAC-3′ and Rv 5′-CCCA
TCATCATGACCTGGATT-3′; p16Inka Fw:5′-CGTACCCCGATTCAGGTGAT-
3′ and Rv: 5′-TTGAGCAGAAGAGCTGCTACGT-3′; p19Arf Fw:5′-TCTTGA
GAAGAGGGCCGCACC-3′ and Rv: 5′-GAATCTGCACCGTAGTTGAGC-3′;
Tnf-α Fw: 5′-CCCACACCGTCAGCCGATTT-3′ and Rv: 5′-GTCTAAGTACTT
GGGCAGATTGACC-3′; Mcp1 Fw: 5′-GCCCAGCACCAGCACCAG-3′ and
Rv: 5′-GGCATCACAGTCCGAGTC-3′; Il6 Fw: 5′-CCCAACAGACCTGTCT-3′
and Rv: 5′-CCAGTTTGGTAGCATCC-3′; Irs1 Fw: 5′-CGGAGAGCGATGGC
TTCTC-3′ and Rv: 5′-GTTTGTGCATGCTCTTGGGTTT-3′.2.9. Analysis in bone marrow-derived macrophages
Murine bone marrow-derived macrophages from both groups of
mice, were obtained from femoral bone marrow cells differentiated
(1 × 106 cells/mL) for 7 days in DMEM P/S, 10% foetal bovine serum
and 10% L929-cell conditioned medium (source of macrophage colony-
stimulating factor). Proliferation was evaluated by incorporation of
bromodeoxyuridine (BrdU, 18 h, 50 μM, Sigma) in macrophages grown
on coverslips, detected by immunoﬂuorescence with a monoclonal
anti-BrdU Alexa Fluor-488 antibody (1/200, clone MoBu B35130,
Invitrogen) of ﬁxed (PFA 4%/PBS) and permeabilised (0.5% Triton X-
100, 2MHCL) cells [36]. Total cell countwas performed by nuclear stain-
ing with 4′,6-diamidino-2-phenylindole (DAPI) (D1306, ThermoFisher,
Kidlington, UK). Coverslips were mounted with SlowFade Gold antifade
reagent and analysed by ﬂuorescence microscopy with an inverted ﬂuo-
rescence microscope. Two independent experiments were performed
with 5 replicates each (per genotype) and 4–6 coverslips per replicate.
The proliferation rate was determined as the percentage of BrdU-
positive cells relative to the total cell count analysed in 10 randomly
selected ﬁelds (with a total of 600–1000 cells) of 4–6 independent cov-
erslips per replicate. Macrophage apoptosis was analysed in cells irradi-
ated or not irradiated with ultraviolet (UV) light (60 J/m2) and rested
for 18 h. Cell apoptosis was determined by ﬂow cytometry as the
SubG0 peak subpopulation (in percentage) in cells ﬁxed with 80% etha-
nol (−20 °C for 30 min) and stained with propidium iodide (50 μg/mL,
containing RNase A, Sigma) as described [35]. Two experiments were
performed, each with quadruplicates, and between 5000–15,000 events
were analysed in each replicate.2.10. In vivo insulin signalling studies
Insulin signalling experiments were performed in 15 h-fasted mice,
which were challenged or not challenged with recombinant murine
Tnf-α (2 μg/kg of BW, PeproTech, London, UK) for 2 h and stimulated
or left untreated with Actrapid (0.25 U insulin/g of BW) for 5 min [29].
The liver and skeletalmusclewere rapidly removed and frozenwith liq-
uid N2 for further analysis.
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Data are presented as mean ± SEM. Differences were evaluated by
one-way ANOVA, two-way ANOVA or Student's t-tests (GraphPad
Prism Software). Signiﬁcancewas set at p ≤ 0.05 and outliers were iden-
tiﬁed by Grubb's test.
3. Results
3.1. Increased dosage of the Ink4/Arf locus ameliorates glucose intolerance
induced by partial deﬁciency of Irs2
To analyse whether the Ink4/Arf transgene was active in
Irs2+/−SuperInk4/Arf mice, the protein expression was examined
by Western blot analysis. In agreement with previous studies [29,31],
there was augmented expression of p15Ink4b and p16Ink4a proteins in
the liver of 1-year-old Irs2+/−SuperInk4/Arf (Fig. 1A) compared with
that for Irs2+/− (p b 0.03 and p b 0.02, respectively) and WT
(p b 0.003 and p b 0.0004, respectively) mice. There were no signiﬁcant
changes observed in the p19Arf protein (Fig. 1A). Similarly, the pancre-
atic islet showed an enhanced expression of p15Ink4b, p16Ink4a and
p19Arf proteins in Irs2+/−SuperInk4/Arf mice (Fig. 1B, p b 0.0008,
p b 0.0002 and p b 0.05, respectively) compared with that for WT
mice. Interestingly, Irs2+/− mice also displayed an enhanced ex-
pression of p15Ink4b protein in the islets (Fig. 1B, p b 0.008) compared
with those in WT mice. Additionally, a comparison between
Irs2+/−SuperInk4/Arf mice and Irs2+/− mice showed as well en-
hanced p16Ink4a protein levels in the ﬁrst (Fig. 1B, p b 0.0002).
Thus, an extra dosage of the locus in Irs2+/−SuperInk4/Arf mice in-
creased the expression of the locus proteins in the liver and in pan-
creatic islets.
No changes were observed in body weight among groups (Fig. 2A).
Body fat mass and body fat mass distribution percentages were also
similar (Fig. 2B). Themetabolic characterisation of mice showed similarFig. 1. Ink4/Arf locus expression in liver and islets fromWT, Irs2+/− and Irs2+/−SuperInk4/Arf
isolated islets. The quantiﬁcations in the graphs represent the average of 3–8 independent blots
the different proteins and β-actin. Representative blots are shown on the right of the panels. D
ANOVA test.fasting glucose levels between Irs2+/− and Irs2+/−SuperInk4/Arf, but
these were increased compared with those for WT mice (Fig. 2C, left
panel, p b 0.002 and p b 0.04 respectively). Fasting insulin levels were
signiﬁcantly increased in Irs2+/− mice compared with those for WT
and Irs2+/−SuperInk4/Arf (Fig. 2C, middle panel, p b 0.02 for both). In
agreement with these results, HOMA-IR was also higher in Irs2+/−
mice compared with those forWT and Irs2+/−SuperInk4/Arf (Fig. 2C,
right panel, p b 0.02 and p b 0.04, respectively). No changes either in
fasting insulin levels or in HOMA-IR (Fig. 2C) were observed between
WT and Irs2+/−SuperInk4/Arfmice. Analysis of the glucose tolerance,
determined by the area under the curve parameter (glucose curve vs
time, AUCglucose) obtained from the GTT, showed an increased glucose
intolerance in Irs2+/− (Fig. 2D, upper panel, p b 0.04) compared with
that for WT mice. Nevertheless, an increased dosage of the Ink4/Arf
locus in Irs2+/− mice improved glucose tolerance, as revealed by a
reduced AUCglucose in Irs2+/−SuperInk4/Arfmice compared with that
for Irs2+/− mice (Fig. 2D, upper panel, p b 0.003). An analysis of the
glucose-stimulated insulin release during the GTT, expressed as
AUCinsulin, did not show signiﬁcant differences among the three groups
(Fig. 2D, lower panel), although insulin secretion was slightly higher
in Irs2+/− mice during the test. The analysis of insulin sensitivity by
ITT demonstrated increased IR, as shownby an increase in theAUCglucose
parameter, in Irs2+/−mice compared with that forWTmice (Fig. 2E,
p b 0.05). The presence of an extra locus dosage in Irs2+/−SuperInk4/
Arfmice improved insulin sensitivity, as revealed by reduced AUCglucose
during the ITT, compared with that for Irs2+/−mice (Fig. 2E, p b 0.02)
and this parameter was similar to that exhibited by WT mice. Hence,
these results indicate that partial deﬁciency of Irs2 in one-year old
mice produces glucose intolerance and IR which are ameliorated with
an increased dosage of the Ink4/Arf locus.
Next, the islet characterisation by insulin immunohistochemistry of
pancreatic cross-sections was performed. An analysis of the pancreatic
islet number did not show differences in the islet number among geno-
types (Fig. 3A, left panel). To the contrary, compared with that formice. p15Ink4b, p16Ink4a, and p19Arf protein expression levels in (A) liver and (B) pancreatic
. Protein lysates (100 μg)were subjected toWestern blot analysis using antibodies against
ata are presented as mean ± SEM. The statistical analysis was carried out using one-way
Fig. 2. Increased Ink4/Arf expression in Irs2+/−mice improves glucosemetabolism and insulin sensitivity. (A) Bodyweight, (B) body fat mass (left panel) and body fat mass distribution
(right panel). (C) Fasting plasma glucose levels, fasting insulin levels and HOMA-IR index inWT, Irs2+/− and Irs2+/−SuperInk4Arfmice. (D) Plasmatic glucose (top panel) and insulin
(lower panel) levels at the different time points during the GTT inWT, Irs2+/− and Irs2+/−SuperInk4/Arfmice which were used to calculate the AUCglucose and AUCinsulin (right panels).
(E) Glucose levels (percentage relative to the initial glucose levels) during the ITT in 4 h-fastedWT, Irs2+/− and in Irs2+/−SuperInk4/Arfmice. The right graph displays the AUCglucose for
the three groups of mice. The statistical analysis was performed using one-way ANOVA.
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creased in Irs2+/−SuperInk4/Arf mice (Fig. 3A, right panel, p b 0.04)
and this was similar to that observed forWTmice. Furthermore, a de-
creased β-cell content in Irs2+/−SuperInk4/Arfmice coincided with a
reduced β-cell proliferation measured as Ki67-positive cells compared
with those for both WT and Irs2+/− mice (Fig. 3B, p = 0.05 and
p b 0.009 respectively). Whilst these results are consistent with the
established role of the Ink4/Arf locus as a key regulator of the regenera-
tive potential of β-cells and with the increased expression of the locus
proteins in pancreatic islets, they do not explain the improved glucose
tolerance and insulin sensitivity in Irs2+/−SuperInk4/Arfmice.3.2. Reduced hepatic inﬂammation in Irs2+/−SuperInk4/Arf mice
Bearing in mind that hepatic steatosis and inﬂammation might be
associated with whole-body insulin sensitivity [37], analysis of the
livers from WT, Irs2+/− and Irs2+/−SuperInk4/Arf mice was per-
formed. Irs2+/−mice exhibited an enhanced triglyceride content com-
pared with those for WT and Irs2+/−SuperInk4/Arf mice (Fig. 4A,
p b 0.0002 and p b 0.002, respectively). Irs2+/−SuperInk4/Arf andWT
mice displayed similar hepatic triglyceride content. Consistent with
these results, immunohistological analysis showed that Irs2+/−mice
had an augmented number of cells with lipid droplets (LD) (Fig. 4A,
Fig. 3. Pancreatic islet characterisation inWT, Irs2+/− and Irs2+/−SuperInk4/Arfmice. (A) Relative islet number andβ-cell area percentage identiﬁed by anti-insulin immunohistochem-
istry. (B) Quantiﬁcation of proliferating islet cells relative to islet total cell count determined as Ki67-positive cells by immunohistochemistry. Representativemicrographs are shown. Data
are presented as mean ± SEM. Statistical analysis was performed using the one-way ANOVA test.
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theless, an extra dosage of the locus in Irs2+/−SuperInk4/Arfmice, sig-
niﬁcantly reduced the number of cells with LD (Fig. 4A, p b 0.02) as well
as the LD average size (Fig. 4A, p b 0.02). An immunohistochemical anal-
ysis of the F4/80 macrophage marker demonstrated an increased
(Kuppfer) macrophage inﬁltration in the liver of Irs2+/− mice com-
pared with that inWTmice (Fig. 4B, p b 0.02). Conversely, macrophage
numbers in the livers of Irs2+/−SuperInk4/Arf mice were similar to
those of WT mice and this was signiﬁcantly reduced compared with
the macrophage number in Irs2+/− mice (Fig. 4B, p b 0.04). Hepatic
mRNA levels of the proinﬂammatory Mcp1 and Tnf-α mediators were
higher in Irs2+/− mice when compared with those of both WT as
well as Irs2+/−SuperInk4/Arf (Fig. 4C, p b 0.001 and p b 0.003 vs WT;
p b 0.02 and p b 0.002 vs Irs2+/−SuperInk4/Arf) indicating a higher in-
ﬂammatory state of the liver. These results demonstrate that in Irs2+/−
mice, IR and glucose dysbalance is accompanied by hepatic inﬂamma-
tion and steatosis and that an increase of the Ink4/Arf locus prevents
the development of these metabolic alterations.
Further analysis of systemic inﬂammation demonstrated increased
MCP1 and TNF-α plasma levels in Irs2+/− compared with those forWTmice (Fig. 5A, p b 0.05 and p b 0.03, respectively). Consistent with
the results above, the levels of these cytokines were signiﬁcantly re-
duced in Irs2+/−SuperInk4/Arf mice (Fig. 5A, p b 0.005 and p b 0.01).
Similarly, an analysis of circulating leukocytes showed monocytosis in
Irs2+/− mice compared with that for both WT (Fig. 5B, p b 0.0005)
and Irs2+/−SuperInk4/Arf mice (Fig. 5B, p b 0.03). Further monocyte
analysis of monocyte subpopulation demonstrated an enhanced per-
centage of the proinﬂammatory Ly6Chi-monocyte subset in Irs2+/−
mice compared with WT mice and Irs2+/−SuperInk4/Arf mice
(Fig. 5C, left panel p b 0.007 and p b 0.03, respectively). Nevertheless,
the percentage of the patrolling Ly6Clow-monocytes was signiﬁcant-
ly lower in Irs2+/− mice compared with those for WT mice and
Irs2+/−SuperInk4/Arf mice (Fig. 5C, right panel, p b 0.003 and p =
0.05, respectively). T-cell lymphocyte characterisation showed a de-
creased number of total CD3+ (Fig. 6A, p b 0.004 and p = 0.05) in
Irs2+/− mice and no differences in T-cell activation (doubly positive
CD3+CD69+ cells). Further characterisation of T-cells demonstrated
that, in agreementwith the observed increased inﬂammatory phenotype,
the activation of both T-lymphocyte subtypes, CD4+ and CD8+ cells,
was signiﬁcantly increased in Irs2+/−mice compared with that forWT
Fig. 4. Liver characterisation inWT, Irs2+/− and Irs2+/−SuperInk4/Arfmice. (A)Hepatic TG content (toppanel) and lipid droplet (LD) content expressed as number of cellswith LD andas
the hepatic average LD size (lower panels). (B)Macrophage content (F4/80+ cells relative to hepatic area) in hepatic cross-sections ofWT, Irs2+/− and Irs2+/−SuperInk4/Arfmice. Rep-
resentative images are shown. (C)Mcp1 and Tnf-α hepatic mRNA levels normalised to cyclophilin and relativised toWTmouse mRNA levels inWT, Irs2+/− and Irs2+/−SuperInk4/Arf
mice. The statistical analysis was performed using one-way ANOVA.
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locus, these parameters were restored, and the Irs2+/−SuperInk4/Arf
mice displayed a signiﬁcantly lower CD4+ and CD8+ T-cell activation
when compared with Irs2+/−mice (Fig. 6B, p b 0.03 and p b 0.05, re-
spectively). Altogether these results indicate that Irs2 haploinsufﬁciency
in mice produces a systemic proinﬂammatory phenotype consisting of
increased inﬂammatory cells and mediators which are reduced in mice
that have an extra dosage of the Ink4/Arf locus.
3.3. Characterisation of Irs2+/−SuperInk4/Arf mouse macrophages
To analyse whether the systemic inﬂammatory changes upon the
augmented expression of Ink4/Arf locus were related to differential
macrophage properties, these were also characterised. An analysis
of isolated macrophages demonstrated enhanced mRNA levels of
the Mcp1, Tnf-α and Il6 cytokines in Irs2+/− macrophages com-
pared with those for WT (Fig. 7A, p b 0.05, p b 0.008 and p b 0.004,
respectively) and Irs2+/−SuperInk4/Arf macrophages (Fig. 7A,
p b 0.02, p b 0.03 and p b 0.01, respectively). A functional analysis
of these cells showed that the decreased inﬂammatory phenotype in
Irs2+/−SuperInk4/Arf macrophages was associated with an increased
activity of the Ink4/Arf locus measured as decreased proliferation
(Fig. 7B, p b 0.0008 vs Irs2+/− and p b 0.03 vsWTmacrophages) and
increased UV-induced apoptosis (Fig. 7C, p b 0.05 vs Irs2+/− and
p b 0.0003 vs WT macrophages). An expression analysis of the locus
genes demonstrated an increased expression of p15Ink4b and p19Arf
mRNA levels in Irs2+/−SuperInk4/Arf mouse macrophages compared
with that for WT and Irs2+/−mouse mRNA levels (Fig. 7D, p = 0.05
and p b 0.02 vs WTmice; p b 0.006 and p b 0.007 vs Irs2+/−mice). In-
terestingly, the mRNA levels of p16Ink4a (Fig. 7D, central panel) were
the lowest in Irs2+/− macrophages (p b 0.03 vs WT and p b 0.04vs Irs2+/−SuperInk4/Arf). Thus, Irs2+/−SuperInk4/Arfmouse mac-
rophages display a decreased inﬂammatory phenotype and this is
linked to enhanced expression and functionality of the transgene.
3.4. In vivo infusion of TNF-α in Irs2+/−SuperInk4/Arf mice decreases in-
sulin signalling and enhances stress-related pathways
Improved glucose homeostasis induced by an increased dosage of
the Ink4/Arf locus has been associated with increased canonical insulin
IRS-mediated signalling [29]. Consistent with IR, in vivo insulin signal-
ling analysis demonstrated decreased activation of the insulin-
stimulated phosphotyrosine(pTyr)IRS1 protein levels in the liver of
Irs2+/− mice compared with those for WT mice (Fig. 8A, p = 0.05).
Consistent with restored insulin sensitivity and glucose homeostasis,
Irs2+/−SuperInk4/Arfmice displayed enhanced pTyrIRS1 protein levels
compared with those for Irs2+/−mouse levels (Fig. 8A, p b 0.005). As
before, activation levels of this pathway in Irs2+/−SuperInk4/Arfmice
were undistinguishable from those in WT mice. No changes in IRS1
total protein or mRNA expression were observed among the different
mouse groups (Fig. 8B). Similarly, analysis of the insulin-stimulated
pAKT1/2 protein levels in liver showed that they were also decreased
in Irs2+/−mice compared with those forWTmice (Fig. 8C, top panel,
p b 0.02). Consistent with the results above, pAKT1/2 protein levels
in liver of Irs2+/−SuperInk4/Arfmice were similar to that ofWTmice
and were signiﬁcantly enhanced compared with Irs2+/−mouse levels
(Fig. 8C, top panel, p b 0.006). Similarly, pAKT1/2 protein levels
were also decreased in the skeletal muscle from Irs2+/− mice com-
pared with the levels observed in the skeletal muscle from both WT
and SuperInk4/Arf mice (Fig. 8C, lower panel, p = 0.05 and p b 0.002,
respectively). These results demonstrate that improved glucose homeo-
stasis, reduced hepatic steatosis and decreased inﬂammation in
Fig. 5. Systemic inﬂammation in WT, Irs2+/− and Irs2+/−SuperInk4/Arf mice. (A) MCP1 and TNF-α circulating plasma levels in WT, Irs2+/− and Irs2+/−SuperInk4/Arf mice.
(B) Percentage of circulating monocytes identiﬁed as CD45+CD115+ cells by ﬂow cytometry. (C) Percentage of Ly6Chi and Ly6Clow cells in CD45+CD115+ blood monocytes inWT,
Irs2+/− and Irs2+/−SuperInk4/Arfmice. Representative plots of the ﬂow cytometry analysis are shown. The statistical analysis was performed using the one-way ANOVA.
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AKT1/2-signalling compared with that for Irs2+/−mice, and that the
locus induces a phenotype similar to the one observed forWTmice.
Given the observed differences in inﬂammation and that cytokine
levels might impair insulin signalling and sensitivity through activa-
tion of the stress SAPK/JNK-pathway and the subsequent IRS1-
inactivation by Serine307-phosphorylation (pSer307IRS1) [38], we
next explored whether the infusion of TNF-α could modulate signal-
ling in Irs2+/−SuperInk4/Arfmice. Analysis of the stress-pathway of
insulin-stimulated mice revealed decreased levels of the inactive
pSer307IRS1 (Fig. 9A, top panel, p = 0.05) and pSAPK/JNK proteins
(Fig. 9A, lower panel, p b 0.04) in liver from Irs2+/−SuperInk4/Arf
mice compared with those for Irs2+/− mice. Nevertheless, an
in vivo infusion of TNF-α in Irs2+/−SuperInk4/Arf mice increased
pSer307IRS1 and pSAPK/JNK protein levels in liver and these levels
were comparable to those observed in Irs2+/− mouse liver
(Fig. 9A). As before, insulin-stimulated pAKT protein levels were
higher in insulin-stimulated Irs2+/−SuperInk4/Arf mice compared
with those for Irs2+/−mice (Fig. 9B, p b 0.02) but these were similar
upon acute treatmentwith TNF-α cytokine. Altogether, these results in-
dicate that the restored insulin-signalling, inﬂammation and glucose
homeostasis in Irs2+/−SuperInk4/Arf mice are associated with areduced activity of the stress SAPK/JNK-signalling pathway and en-
hanced canonical insulin-AKT-signalling. Given that cytokine treatment
abolishes the improved insulin-signalling in Irs2+/−SuperInk4/Arf
mice and that an increased locus is associated with reduced proinﬂam-
matory macrophage phenotype and inﬂammation, it is conceivable
that, by reducing inﬂammation and cytokine levels, the locus restores
insulin signalling and glucose homeostasis.
4. Discussion
Genetic variants in the close vicinity of the human Ink4/Arf locus
have been linked to T2DM [13–20]. It has been previously shown that
patients with IR and metabolic syndrome have reduced IRS2 expres-
sion [5,7,9–12]. The present study, demonstrates that haploinsufﬁciency
for Irs2 in one-year-old mice produces glucose intolerance and IR com-
paredwith age-matchedWTmice. Upon increased Ink4/Arf gene dosage,
however, Irs2+/−mice signiﬁcantly improved glucose homeostasis, in-
sulin sensitivity and signalling.Moreover, glucosemetabolism improve-
ment in Irs2+/−SuperInk4/Arf mice was associated with restored
hepatic homeostasis and decreased systemic inﬂammation compared
with Irs2+/−mice, and all these parameters were undistinguishable
from those observed in age-matched WT mice. Thus, compared with
Fig. 6. Circulating T-lymphocyte characterisation in WT, Irs2+/− and Irs2+/−SuperInk4/Arf mice. (A) Circulating total and activated T-lymphocytes identiﬁed as CD3+ cells and
CD3+CD69+ cells respectively. (B) Quantiﬁcation of CD4+ and CD8+ cells and activated CD4+CD69+ and CD8+CD69+ cells. Representative plots of the ﬂow cytometry analysis
are shown. The statistical analysis was performed using one-way ANOVA.
1737Á. Vinué et al. / Biochimica et Biophysica Acta 1852 (2015) 1729–1742Irs2+/− mice, Irs2+/−SuperInk4/Arf mice displayed reduced hepatic
steatosis, macrophage inﬁltration, as well as Tnf-α andMcp1 cytokine
mRNAexpression. Similarly, circulatingMCP1 andTNF-α cytokine levels,
proinﬂammatory Ly6Chi-monocytes and T(CD4+ and CD8+)-cell acti-
vation were similar between WT and Irs2+/−SuperInk4/Arf mice but
these proinﬂammatory cells and mediators were signiﬁcantly lower
than those in IR Irs2+/− mice. Consistent with these results, isolated
Irs2+/−SuperInk4/Arfmouse macrophages exhibited a diminished pro-
inﬂammatory phenotype and displayed decreased Tnf-α, Mcp1 and Il6
mRNA cytokine expression which was linked to enhanced expression
and functionality of the Ink4/Arf locus. In vivo insulin signalling experi-
ments revealed that restored hepatic function, glucose homeostasis
and decreased inﬂammation in Irs2+/−SuperInk4/Arfmice was accom-
panied by improved insulin-IRS1/AKT-dependent signalling and reduced
activation of the stress SAPK/JNK/IRS1-pathway compared with that inIrs2+/−mice. Interestingly, in vivo treatment of Irs2+/−SuperInk4/Arf
mice with murine recombinant TNF-α enhanced the above-mentioned
stress-pathway and decreased the canonical insulin AKT-dependent
pathway. Therefore, lower levels of inﬂammatory mediators and de-
creased inﬂammatory cell activation in Irs2+/−SuperInk4/Arf mice
could potentially be, at least in part, one of the driving forces by which
the locus ameliorates hepatic IR and restores glucose homeostasis in
Irs2+/−mice.
Previous studies have shown that an increased expression of the
Ink4/Arf locus protects against general ageing, provides cancer resis-
tance and restores glucose metabolism derangement associated with
ageing inWTmice [29,31,32]. The present study demonstrates that in
one-year old Irs2-haploinsufﬁcient mice, which exhibit glucose intoler-
ance and IR, an extra dosage of the Ink4/Arf locus is sufﬁcient both to re-
store glucose tolerance, insulin sensitivity and signalling, as well as to
Fig. 7. Inﬂammatory and functional activity in WT, Irs2+/− and Irs2+/−SuperInk4/Arf mouse macrophages. (A) mRNA expression of Mcp1, Tnf-α and Il6 in WT, Irs2+/− and
Irs2+/−SuperInk4/Arf mouse macrophages. (B) Percentage of proliferating macrophages analysed by BrdU incorporation and detected by immunoﬂuorescence. White arrows point
to BrdU+ cells. (C) Apoptosis analysis inWT, Irs2+/− and Irs2+/−SuperInk4/Arfmouse macrophages expressed as SubG0 cell percentage. (D) mRNA expression of p15Ink4b, p16Ink4a
and p19Arf in WT, Irs2+/− and Irs2+/−SuperInk4/Arf mouse macrophages. The mRNA expression levels were normalised to cyclophilin mRNA levels and relativised to WT mouse
mRNA expression. Representative images and plots are shown. The statistical analysis was performed using the one way ANOVA (A, B, D) and two-way ANOVA (C) tests.
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the study provides new experimental data supporting a protective
role of the locus in IR-syndromes provoked by insulin IRS2-
impaired signalling and is in the line of human investigations indi-
cating that genetic variants within the CDKN2B are associated with
changes in HOMA-IR [25].Lowgrade inﬂammation and steatosis in liver are not sufﬁcient to in-
duce IR [39], but they have been frequently linked to hepatic IR [37,40,
41].Moreover, previous studies have indicated that alterations in hepat-
ic insulin sensitivity and function profoundly affect whole body glucose
homeostasis [8]. The study presented here has extended the beneﬁcial
mechanisms of the Ink4/Arf locus to the development of the hepatic
Fig. 8. Insulin signalling inWT, Irs2+/− and Irs2+/−SuperInk4/Arfmice. (A) Analysis of phosphoTyr(pTyr)IRS1 protein levels in liver lysates subjected to immunoprecipitationwith anti-
IRS1. pTyr protein levels were relativised to the unstimulated mouse sample of the same genotype. (B) Total IRS1 protein levels analysed by Western blot of protein lysates
immunoprecipitatedwith the same antibody. Protein IRS1 levelswere relativised toWTmice antibody (left panel) andmRNA expression of IRS1 (right panel). ThemRNA expression levels
were normalised to cyclophilinmRNA levels and relativised toWTmouse mRNA expression. (C) Protein levels of phosphoAKT1/2 (pAKT1/2) and AKT1/2 in liver and skeletal muscle pro-
tein lysates. Phosphorylated formswere normalised to total protein levels and relativised to unstimulatedmouse samples. Representative blots are shown. The statistical analysiswas done
using one-way ANOVA.
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IR in Irs2+/−mice were accompanied by hepatic dysfunction with aug-
mented inﬂammation, macrophage content and steatosis, which in
Irs2+/−SuperInk4/Arf mice were markedly decreased and similar to
that inWTmice. Irs2+/−SuperInk4/Arfmice also displayed diminished
systemic inﬂammation. Levels of circulating proinﬂammatory cytokines,
Ly6Chi-monocytes and activated CD4+/CD8+ T-cell percentages associ-
ated with IR [42,43] were signiﬁcantly reduced compared with those for
Irs2+/−mice. Interestingly, proinﬂammatory Ly6Chi-monocyte subset is
a mainmonocyte subpopulation with an invasive phenotype, andwhose
recruitment is highly dependent on MCP1 cytokine in tissues [44]. On
the contrary, circulating Ly6Clow-monocyte subset levels, a monocyte
subtype previously involved in the patrolling and tissue-repairingfunction [45], were enhanced in Irs2+/−SuperInk4/Arfmice. This could
indicate a higher capacity to resolve inﬂammation in inﬂamed tissues
such as that observed in hepatic steatosis. In addition, Irs2+/−-
SuperInk4/Arfmacrophages displayed lowerMcp1, Tnf-α and Il6 mRNA
expression and survival (decreased proliferation and higher apoptosis)
which was linked to increased expression and activity of the locus.
All these results are consistent with previous studies supporting an
anti-inﬂammatory role of the locus. Thus, an increased Ly6Chi-monocyte
subset percentage has been found in mice with Cdkn2a-ablation in the
myeloid lineage [34], and downregulation of p16Ink4a promotes a
polarisation of human macrophages toward a proinﬂammatory adi-
pose tissue macrophage-phenotype [34,46]. Moreover, local transfer
of p16Ink4a into bone joints also suppresses the expression of
Fig. 9. Effect of TNF-α on the insulin signalling in Irs2+/−SuperInk4/Arfmice. (A) Quantiﬁcation of pSer307IRS1 (top panel) and pSAPK/JNK (lower panel) protein levels in liver frommice
treated with TNF-α or untreated and stimulated with insulin or unstimulated. (B) Protein levels of pAKT1/2 and AKT1/2 in liver of mice treated or not with TNF-α and stimulated or
unstimulatedwith insulin. Phosphorylated formswere normalised to total protein levels and relativised to unstimulatedmice. pSer307IRS1was relativised to unstimulated samples. Rep-
resentative blots are shown. The statistical analysis was done using the Student's t-test.
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[47]. The present macrophage results are also in agreement with
both the well-reported role of the Ink4/Arf locus limiting the prolifer-
ative cellular capacity owing to its role as a cell-cycle inhibitor [19] as
well as with previous studies in Cdkn2a-deﬁcient mice showing that
the locus is a modulator of monocyte/macrophage proliferation [34].
Altogether these studies suggest that reduced inﬂammatory pheno-
type is an intrinsic property of the Ink4/Arf locus-overexpressing
macrophages. Therefore, this could be related with the observed re-
duced systemic inﬂammation and macrophage inﬁltration and could
contribute to the improvement in insulin sensitivity and carbohy-
drate metabolism in Irs2+/− mice.
Previously, it has been shown that the Ink4/Arf locus inWTmice de-
creases the IR associated with ageing by increasing the IRS/AKT-
dependent signalling [29]. In the present study, Irs2+/−SuperInk4/Arf
mice also displayed higher insulin-stimulated IRS1/AKT-activationthan did Irs2+/− mice, which was similar to that observed in WT
mice. Interestingly, restored insulin signalling in Irs2+/−SuperInk4/
Arfmicewas accompanied by a decreased activation of the inﬂammato-
ry stress SAPK/JNK-pathway and reduced inactive pSer307IRS1 protein
levels, which are frequently increased by cytokines [38,40]. In fact, an
infusion in Irs2+/−SuperInk4/Arf mice of TNF-α, a cytokine that im-
pairs insulin-signalling and enhances stress-pathways [48], increased
the activation of the stress SAPK/JNK/pSer307IRS1 signalling-pathway
and reduced canonical insulin AKT-mediated signalling. Consequently,
TNF-α-treated Irs2+/−SuperInk4/Arf mice displayed similar pSAPK/
JNK, pSer307IRS1 and pAKT levels as Irs2+/−mice. Although the phys-
iological relevance of TNF-α does not seem to be clear in cytokine-
receptor loss-of-function studies [49], this cytokine has had a relevant
effect on insulin-signalling in the present study's mouse model. Alto-
gether, the present results suggest that the decreased inﬂammatory
phenotype in Irs2+/−SuperInk4/Arf mice could also be, at least in
1741Á. Vinué et al. / Biochimica et Biophysica Acta 1852 (2015) 1729–1742part, responsible for the improved IR and glucose homeostasis by re-
storing the IRS1/AKT-pathway activation and by decreasing the stress
SAPK/JNK signalling-pathway.
In summary, the present study has shown that one-year old
Irs2+/− mice display systemic inﬂammation, IR, glucose homeostasis
imbalance and hepatic steatosis and that, the increased expression of
the Ink4/Arf locus attenuated inﬂammation, decreased hepatic steatosis
and restored glucose homeostasis. The study demonstrates a protective
role of the Ink4/Arf locus inmetabolic alterations involving IR and defec-
tive insulin signalling that develop with inﬂammation. Moreover, the
present ﬁndings suggest that pharmacologic approaches targeted to
modulate Ink4/Arf locus expression or the use of Ink4/Arf locus mimetic
(i.g. Palbociclib) might be a tentative therapeutic option to restore glu-
cose metabolism derangement and IR associated with inﬂammation.
Future studies arewarranted to address the potential of these therapeu-
tic strategies in IR and diabetes.
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